Predictors of pathologic stage in prostatic carcinoma. The role of neovascularity
- PMID: 7507798
- DOI: 10.1002/1097-0142(19940201)73:3<678::aid-cncr2820730329>3.0.co;2-6
Predictors of pathologic stage in prostatic carcinoma. The role of neovascularity
Abstract
Background: Prostate adenocarcinoma is a significant cause of morbidity and mortality in older men. However, the histologic prevalence far exceeds clinically manifest disease. Increased screening has resulted in the detection of a large number of carcinomas of unknown malignant potential. The authors investigated tumor angiogenesis to predict pathologic stage in prostatic tumors. Angiogenesis in prostatic intraepithelial neoplasia (PIN), a putative premalignant lesion, also was investigated.
Methods: Immunohistochemistry was used to highlight the tumor vasculature. Vessels were quantified using computerized image analysis. A minimum of five randomly selected microscopic fields were measured from each tumor. To investigate PIN, the authors measured vessels per millimeter of gland perimeter, compared with benign glands in the same patient.
Results: Vessel density (vessels per millimeter squared [vv/mm2]) correlated with pathologic stage. The mean vessel density of organ-confined tumors was 80.2 vv/mm2 (95% confidence interval [CI], 71.4-91.0), compared with 110.4 vv/mm2 (95% CI, 97.9-122.8) for tumors with capsular penetration or positive lymph nodes. Logistic regression analysis and modeling showed vessel density superior to histologic grade and preoperative prostate-specific antigen (PSA) level in distinguishing organ-confined tumors from those having extracapsular extension or pelvic lymph node metastasis. PIN in acini and ductules had increased microvascularity relative to benign epithelium in 18 of 25 tumors (P < 0.05).
Conclusions: Neovascularity has been demonstrated to be a prerequisite for tumor progression. These data demonstrate that microvessel density in prostatic carcinoma is an independent predictor of pathologic stage and, presumably, malignant potential. Quantification of tumor angiogenesis may allow stratification of patients to type of treatment and may allow selection of expectant management for men with low tumor microvessel density.
Similar articles
-
CD34 immunohistochemical assessment of angiogenesis as a prognostic marker for prostate cancer recurrence after radical prostatectomy.J Urol. 1998 Aug;160(2):459-65. J Urol. 1998. PMID: 9679898
-
Tumor angiogenesis correlates with progression after radical prostatectomy but not with pathologic stage in Gleason sum 5 to 7 adenocarcinoma of the prostate.Cancer. 1997 Feb 15;79(4):772-9. doi: 10.1002/(sici)1097-0142(19970215)79:4<772::aid-cncr14>3.0.co;2-x. Cancer. 1997. PMID: 9024715
-
Topography of neovascularity in human prostate carcinoma.Cancer. 1995 May 15;75(10):2545-51. doi: 10.1002/1097-0142(19950515)75:10<2545::aid-cncr2820751022>3.0.co;2-x. Cancer. 1995. PMID: 7537624
-
Angiogenesis imaging in the management of prostate cancer.Nat Clin Pract Urol. 2005 Dec;2(12):596-607. doi: 10.1038/ncpuro0356. Nat Clin Pract Urol. 2005. PMID: 16474547 Review.
-
Prostatic intraepithelial neoplasia (PIN) and other prostatic lesions as risk factors and surrogate endpoints for cancer chemoprevention trials.J Cell Biochem Suppl. 1996;25:156-64. J Cell Biochem Suppl. 1996. PMID: 9027613 Review.
Cited by
-
Feasibility of measuring prostate perfusion with arterial spin labeling.NMR Biomed. 2013 Jan;26(1):51-7. doi: 10.1002/nbm.2818. Epub 2012 Jun 7. NMR Biomed. 2013. PMID: 22674425 Free PMC article.
-
Antisense oligonucleotide targeting midkine suppresses in vivo angiogenesis.World J Gastroenterol. 2007 Feb 28;13(8):1208-13. doi: 10.3748/wjg.v13.i8.1208. World J Gastroenterol. 2007. PMID: 17451201 Free PMC article.
-
Roles of nitric oxide in tumor growth.Proc Natl Acad Sci U S A. 1995 May 9;92(10):4392-6. doi: 10.1073/pnas.92.10.4392. Proc Natl Acad Sci U S A. 1995. PMID: 7538668 Free PMC article.
-
The role of the RhoA/Rho kinase pathway in angiogenesis and its potential value in prostate cancer (Review).Oncol Lett. 2014 Nov;8(5):1907-1911. doi: 10.3892/ol.2014.2471. Epub 2014 Aug 21. Oncol Lett. 2014. PMID: 25289078 Free PMC article.
-
A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC).Invest New Drugs. 2011 Dec;29(6):1465-74. doi: 10.1007/s10637-010-9455-x. Epub 2010 May 25. Invest New Drugs. 2011. PMID: 20499131 Free PMC article. Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Other Literature Sources
Medical
Research Materials
Miscellaneous